Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of pembrolizumab plus BCG versus BCG alone in high-risk non-muscle invasive bladder cancer
NL-OMON58811Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- May 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab and bcg vaccine in transitional cell carcinoma of the bladder (TCC) and Bladder cancer in situ (CIS) (5 cohorts), sponsored by Merck & Co. Primary endpoints: Complete Response Rate by blinded independent central review and Event-Free Survival. Started May 2019; status: active, not recruiting.
02
Drugs
pembrolizumabbcg vaccine
03
Conditions
transitional cell carcinoma of the bladder (TCC)Bladder cancer in situ (CIS)
Beyond the preview
Go deeper on NL-OMON58811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58811.